REMO MV 1000

About

This medication provides a triple-action therapy for type 2 diabetes mellitus, combining Remogliflozin, Metformin, and Vildagliptin. Remogliflozin, an SGLT2 inhibitor, lowers blood glucose by increasing glucose excretion in the urine through kidney action. Metformin, a biguanide, reduces hepatic glucose production, decreases intestinal glucose absorption, and enhances insulin sensitivity in peripheral tissues. Vildagliptin, a DPP-4 inhibitor, increases levels of incretin hormones (GLP-1 and GIP), which stimulate glucose-dependent insulin release and suppress glucagon secretion. This comprehensive combination targets multiple pathways involved in glucose dysregulation, offering robust glycemic control by reducing fasting and postprandial glucose levels and significantly lowering HbA1c. It is particularly suitable for patients who require intensive management and have not achieved adequate glycemic targets with dual therapy or monotherapy, serving as an effective adjunct to diet and exercise.

Uses

• Management of type 2 diabetes mellitus in adults.
• Improvement of glycemic control as an adjunct to diet and exercise.
• Reduction of elevated fasting and postprandial blood glucose levels.
• Lowering of HbA1c levels to achieve target glycemic goals.

Directions For Use

Take orally, usually once or twice daily, with meals as directed by your physician. Swallow the tablet whole with water.

Benefits

• Significant reduction in blood glucose levels.
• Improved long-term glycemic control (HbA1c).
• Potential for modest weight reduction.
• May offer cardiovascular protective effects.
• May provide renal protective benefits.
• Comprehensive management through multiple mechanisms of action.

Side Effects

• Genital mycotic infections
• Urinary tract infections (UTIs)
• Increased urination (polyuria)
• Thirst/dehydration
• Nausea
• Diarrhea
• Abdominal discomfort
• Metallic taste
• Headache
• Dizziness
• Hypoglycemia (especially with other antidiabetic agents)
• Rarely, lactic acidosis or diabetic ketoacidosis

Safety Measures

• Alcohol - Avoid excessive alcohol consumption, as it can increase the risk of lactic acidosis (due to Metformin) and may exacerbate dehydration associated with SGLT2 inhibitors.
• Pregnancy - Generally not recommended during pregnancy. Consult your doctor, as the risks and benefits need to be carefully weighed.
• Breastfeeding - Not recommended during breastfeeding due to potential excretion into breast milk and unknown effects on the infant. Consult your doctor.
• Liver - Use with caution in patients with liver impairment. Metformin is contraindicated in severe hepatic dysfunction due to increased risk of lactic acidosis.
• Kidney - Dose adjustment is required based on renal function. Contraindicated in severe renal impairment (eGFR below certain thresholds) for both Metformin and SGLT2 inhibitors.
• Lung - Generally safe for use in patients with stable lung conditions, but severe respiratory illness could be a risk factor for lactic acidosis with Metformin.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.